{'52WeekChange': 0.14975035,
 'SandP52WeekChange': 0.0644362,
 'address1': '500 River Ridge Drive',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 6.95,
 'askSize': 3200,
 'averageDailyVolume10Day': 1477912,
 'averageVolume': 1435858,
 'averageVolume10days': 1477912,
 'beta': 1.418487,
 'beta3Year': None,
 'bid': 6.86,
 'bidSize': 1400,
 'bookValue': 0.313,
 'category': None,
 'circulatingSupply': None,
 'city': 'Norwood',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 7.04,
 'dayLow': 6.675,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -5.824,
 'enterpriseToRevenue': 12.863,
 'enterpriseValue': 463326528,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 7.4601426,
 'fiftyTwoWeekHigh': 8.779,
 'fiftyTwoWeekLow': 3.29,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 63842338,
 'forwardEps': -1.6,
 'forwardPE': -4.31875,
 'fromCurrency': None,
 'fullTimeEmployees': 141,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.049289998,
 'heldPercentInstitutions': 0.41182,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/corbuspharma.com',
 'longBusinessSummary': 'Corbus Pharmaceuticals Holdings, Inc., a '
                        'clinical-stage pharmaceutical company, focuses on the '
                        'development and commercialization of various '
                        'therapeutics to treat rare, chronic, and serious '
                        'inflammatory and fibrotic diseases. Its lead product '
                        'candidate is lenabasum, a synthetic oral '
                        'endocannabinoid drug that is in Phase III clinical '
                        'trials for the treatment of systemic sclerosis and '
                        'dermatomyositis, and in Phase IIb clinical trials to '
                        'treat systemic lupus erythematosus and cystic '
                        'fibrosis. The company is also developing CRB-4001, a '
                        'peripherally-restricted CB1 inverse agonist, for '
                        'nonalcoholic steatohepatitis and other fibrotic '
                        'diseases. It has a licensing agreement with Jenrin '
                        'Discovery, LLC to develop and commercialize the '
                        'licensed products, which includes the Jenrin library '
                        'of approximately 600 compounds and multiple issued '
                        'and pending patent filings; and strategic '
                        'collaboration with Kaken Pharmaceutical Co., Ltd. for '
                        'the development and commercialization of lenabasum in '
                        'Japan. The company was founded in 2009 and is based '
                        'in Norwood, Massachusetts.',
 'longName': 'Corbus Pharmaceuticals Holdings, Inc.',
 'market': 'us_market',
 'marketCap': 500908640,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_254045988',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -74875712,
 'nextFiscalYearEnd': 1640908800,
 'open': 6.79,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '617-963-0100',
 'previousClose': 6.8,
 'priceHint': 2,
 'priceToBook': 22.076677,
 'priceToSalesTrailing12Months': 13.9064245,
 'profitMargins': -2.07873,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 7.04,
 'regularMarketDayLow': 6.675,
 'regularMarketOpen': 6.79,
 'regularMarketPreviousClose': 6.8,
 'regularMarketPrice': 6.79,
 'regularMarketVolume': 1930725,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 72490400,
 'sharesPercentSharesOut': 0.1843,
 'sharesShort': 13361657,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 11147694,
 'shortName': 'Corbus Pharmaceuticals Holdings',
 'shortPercentOfFloat': 0.2345,
 'shortRatio': 7.35,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'CRBP',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.138,
 'twoHundredDayAverage': 6.346151,
 'volume': 1930725,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.corbuspharma.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02062'}